

Imatinib
Essential medicine status
General description
Imatinib is a BCR-ABL tyrosine kinase inhibitor used in treatment protocols for various leukaemias and solid tumours.
INN
Imatinib
ATC codes
[L01EA01](#)
Medicine type
Chemical agent
EML status history
First added in 2015 ([TRS 994](#)) for [Chronic myeloid leukaemia, not elsewhere classified](#)
Added in 2015 ([TRS 994](#)) for [Gastrointestinal stromal tumour of unspecified gastrointestinal sites](#)
Added in 2021 ([TRS 1035](#)) for [B lymphoblastic leukaemia or lymphoma with t\(9:22\) \(q34;q11.2\); BCR-ABL1](#)
Wikipedia
[Imatinib](#)
DrugBank
[Imatinib](#)
Recommendations
Section
Targeted therapies

- Oral > Solid: 100 mg; 400 mg

Indications
[Chronic myeloid leukaemia, not elsewhere classified](#) [Gastrointestinal stromal tumour of unspecified gastrointestinal sites](#) [B lymphoblastic leukaemia or lymphoma with t\(9:22\) \(q34;q11.2\); BCR-ABL1](#)